111 results
Page 3 of 6
8-K
EX-2.1
5thx1oz6i6k84b
26 Oct 21
EyeGate adds Bayon Therapeutics’ portfolio of vision-restoring small molecules to its development pipeline
7:00am
8-K
EX-10.1
obys7cesl33cgf83
10 Aug 21
EyeGate Announces $10.75 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
6:55am
8-K
EX-99.1
9ktwrl0hco6fu4zp
26 Jul 21
EyeGate Pharmaceuticals Announces Appointment of Brian M. Strem, Ph.D., as President and Chief Executive Officer
4:18pm
8-K
EX-99.1
v5hf41ioyqh5r6uscyp
27 May 21
Regulation FD Disclosure
7:01am
8-K
EX-10.1
86csrlmh7s7xxapeps9
1 Feb 21
Departure of Directors or Certain Officers
6:55am
8-K
EX-10.2
s7xdkdc
6 Jan 21
EyeGate Enters Into Agreement for $8.0 Million Private Placement
6:55am
8-K
EX-10.1
jpn0xoocj1b4iwnp
6 Jan 21
EyeGate Enters Into Agreement for $8.0 Million Private Placement
6:55am
8-K
EX-10.1
buzc3im0y6j
21 Dec 20
EyeGate Pharma Announces Transformative Acquisition of Panoptes Pharma
6:55am
8-K
EX-2.1
jp8rrxyjgi739b41u
21 Dec 20
EyeGate Pharma Announces Transformative Acquisition of Panoptes Pharma
6:55am